NCT06147921View on ClinicalTrials.gov

Phase 1, SAD/MAD of Verasone™ Administered by Sinonasal Irrigation in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

December 15, 2023

Primary Completion Date

December 13, 2024

Study Completion Date

December 13, 2024

Conditions
Healthy Volunteers
Interventions
DRUG

Verasone

Administered by sinonasal irrigation.

Trial Locations (1)

3004

Nucleus Network, Melbourne

Sponsors
All Listed Sponsors
collaborator

Diceros Therapeutics Australia Pty Ltd

INDUSTRY

lead

Diceros Therapeutics

INDUSTRY

NCT06147921 - Phase 1, SAD/MAD of Verasone™ Administered by Sinonasal Irrigation in Healthy Participants | Biotech Hunter | Biotech Hunter